非骨髓瘤性免疫增殖性疾病中浆细胞的 CD200 表达：临床病理特征，并与浆细胞骨髓瘤进行比较。

CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma.

机构信息

Dept of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

出版信息

Am J Clin Pathol. 2012 Dec;138(6):867-76. doi: 10.1309/AJCP3TQR1TFHHGAS.

Abstract

The majority of plasma cell myelomas (PCMs) are positive for CD200, a membrane protein with immunosuppressive function. There are no flow cytometry data in the literature on plasma cell CD200 expression in other immunoproliferative disorders. Therefore we used flow cytometry to study the expression of CD200 on plasma cells in diagnostic bone marrow aspirates from 61 patients with monoclonal gammopathy of undetermined significance (MGUS) and 10 patients with lymphoplasmacytic lymphoma (LPL). For comparison, we evaluated CD200 expression in 74 PCM bone marrow biopsies. Thirty-three (54.1%) of 61 MGUS cases and 2 (20.0%) of 10 LPL cases were CD200+. Comparative clinicopathologic parameters for MGUS cases, based on CD200 expression status, showed no differences between the 2 groups. The proportion of CD200+ PCMs (73.0%) in our series was significantly higher than that of CD200+ MGUS (P = .030) and CD200+ LPL (P = .002) cases.

摘要

大多数浆细胞骨髓瘤（PCM）为 CD200 阳性，CD200 是一种具有免疫抑制功能的膜蛋白。其他免疫增殖性疾病浆细胞 CD200 表达的流式细胞术数据在文献中尚无记载。因此，我们使用流式细胞术研究了 61 例意义未明单克隆丙种球蛋白血症（MGUS）和 10 例淋巴浆细胞淋巴瘤（LPL）患者的诊断性骨髓抽吸物中浆细胞的 CD200 表达。作为对照，我们评估了 74 例 PCM 骨髓活检的 CD200 表达。61 例 MGUS 病例中有 33 例（54.1%）和 10 例 LPL 病例中有 2 例（20.0%）为 CD200+。基于 CD200 表达状态的 MGUS 病例的比较临床病理参数在两组之间无差异。我们的研究中 CD200+ PCM（73.0%）的比例明显高于 CD200+ MGUS（P =.030）和 CD200+ LPL（P =.002）病例。